AssureRx Health Receives Accreditation from the College of American Pathologists (CAP) for the Delivery of High-Quality, Reliable Laboratory Pharmacogenetic Testing Services that Meet or Exceed Regulatory Laboratory Standards
AssureRx Health, Inc. today announced that it has received accreditation from the College of American Pathologists (CAP) for the delivery of high-quality, reliable laboratory pharmacogenetic testing services that meet or exceed regulatory laboratory standards and ensure commitment to patient care.
The goal of the CAP Laboratory Accreditation Program is to improve patient safety by advancing the quality of pathology and laboratory services through education, standard setting, and ensuring that laboratories meet or exceed regulatory requirements. An accredited laboratory is inspected by an accrediting organization approved by the Centers for Medicare and Medicaid Services (CMS) and deemed as equivalent to or more stringent than CMS’s regulatory requirements. CAP accreditation now places AssureRx Health among an exclusive group of more than 6,000 laboratories worldwide that have met the highest standards of excellence in laboratory medicine.
“We are committed to producing accurate and detailed reports based on our GeneSightRx pharmacogenetic test, which analyzes clinically important genetic variants that may affect an individual patient’s response to specific psychiatric medications,” said Donald R. Wright, Senior Vice President Operations and Technology of AssureRx Health. “CAP accreditation further supports our mission of becoming a leading supplier of treatment support products that assist physicians in making personalized medication choices for behavioral health and other neuropsychiatric disorders.”
CAP is the world’s largest association composed exclusively of pathologists. This medical society serves more than 17,000 physician members and the laboratory community throughout the world. CAP is widely recognized as the leader in laboratory quality assurance through the continuous committed to high quality and cost-effective patient care. For more information regarding CAP please visit
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.